|
Los Angeles, Calif., May 1, 2017. MYnd Analytics (MYAN:OTCQB) has developed the Psychiatric EEG Evaluation Registry, or PEER Online®, a cloud-based platform, which allows physicians to exchange outcome data referenced to their patients' neurophysiology. It provides a vital exchange of information between medical professionals treating patients with mental health issues, to soon be able to significantly impact and improve treatment, while lowering climbing suicide rates, especially among Veterans.
|
|
|
Michael Mantenuto, an actor and hockey player who starred in Disney’s 2004 film “Miracle,” has died of an apparent suicide. He was 35 and after his acting career had joined the military. TMZ reports that the actor died by shooting. In a news release announcing Mantenuto’s death, Col. Guillaume "Will" Beaurpere, the commander for Mantenuto’s 1st Special Forces Group (Airborne), shared the news of his death on Facebook writing, “Those of you that knew Mike will remember him for his passionate love for his family and his commitment to the health of the force".
Unfortunately, Mantenuto's suicide is not uncommon. In July, a statement was made by The Department of Veterans Affairs (VA) after a comprehensive analysis of 55 million Veteran records between 1979 to 2014 from every state in the nation, estimating the number of Veteran deaths by suicide averaged 22 per day. The now Secretary of the Veterans Affairs Dr. David J. Shulkin stated “One Veteran suicide is one too many …. comprehensive data that allows us to make better informed decisions on how to prevent this national tragedy. We as a nation must focus on bringing the number of Veteran suicides to zero."
Companies are working on tools to assist doctors to get patients suffering from depression on the right medication utilizing Mynd Analytics' PEER system, a unique set of reference data and analytic tools. The latest clinical results showed patients of physicians that utilized the PEER recommendations, to make treatment decisions had a 144% improvement in depression scores and a 75% greater reduction in suicidality. Treatments which followed PEER recommendations resulted in 2.5 time’s greater adherence to therapy.
While treatment for mental disorders has doubled in the last 20 years, it is estimated that 17 million Americans have failed two or more medication therapies and suicide rates are climbing. Big data analytics and innovative tools, such as that provided by Mynd Analytics will give hope that we will soon be able to significantly impact and improve treatment while lowering suicide rates
|
|
|
Watch the Report on Mynd Analytics by CBS New York
|
|
|
About MYnd Analytics, Inc.
MYnd Analytics, Inc. provides a unique set of reference data and analytic tools for clinicians and researchers in psychiatry. While treatment for mental disorders has doubled in the last 20 years, it is estimated that 17 million Americans have failed two or more medication therapies for their mental disorders. The Company’s Psychiatric EEG Evaluation Registry, or PEER Online, is a registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on the Company’s original physician-developed database, there are now more than 38,000 outcomes for over 10,000 unique patients in the PEER registry. The goal of PEER Online is to provide objective, personalized data to assist physicians in the selection of appropriate medications.
To read more about the benefits of this patented technology for patients, physicians and payers, please visit www.myndanalytics.com.
|
|
|
If you want to follow all other companies that we cover with more in depth research reports, go to our research site at
www.swiresearch.com/report-index
to download the reports,
or visit
www.stockwatchindex.com
for up to date news on the covered companies.
Please feel free to
re-distribute the reports to your friends and colleagues.
|
|
|
Rainer Poertner - Chief Analyst
|
|
|
S
tockWatchIndex and SWI Research (SWI) are not registered investment advisers and the information provided herein or any other SWI publication is not to be construed as personal financial advice, or a solicitation to buy or sell stock. SWI makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in its publications or on its web sites. Some of the published information has been provided by the companies covered, generated by publicly available sources, or what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or warrant any results from use of the information. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in this publication, any other SWI publication, or its web sites and is not obligated to update and/or correct information. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. SWI expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided.
SWI has not been compensated for this report has not acquired stock of the company mentioned in this report for its portfolio, but
reserves the right to buy or sell positions at its sole
discretion. The included information is subject to change without notice. Please visit
www.swiresearch.com/#!legal-ease/lmvw1
for a full text of our Disclaimer, Privacy policy and Terms of Use.
|
|
|
|
|
|
|
